Advertisement
Research Article

When the Most Potent Combination of Antibiotics Selects for the Greatest Bacterial Load: The Smile-Frown Transition

  • Rafael Pena-Miller,

    Affiliation: Biosciences, Geoffrey Pope Building, University of Exeter, United Kingdom

    X
  • David Laehnemann,

    Affiliation: Evolutionary Ecology and Genetics, Zoological Institute, CAU Kiel, Kiel, Germany

    X
  • Gunther Jansen,

    Affiliation: Evolutionary Ecology and Genetics, Zoological Institute, CAU Kiel, Kiel, Germany

    X
  • Ayari Fuentes-Hernandez,

    Affiliation: Biosciences, Geoffrey Pope Building, University of Exeter, United Kingdom

    X
  • Philip Rosenstiel,

    Affiliation: Institute for Clinical Molecular Biology, CAU Kiel, Kiel, Germany

    X
  • Hinrich Schulenburg,

    Affiliation: Evolutionary Ecology and Genetics, Zoological Institute, CAU Kiel, Kiel, Germany

    X
  • Robert Beardmore mail

    r.e.beardmore@exeter.ac.uk

    Affiliation: Biosciences, Geoffrey Pope Building, University of Exeter, United Kingdom

    X
  • Published: April 23, 2013
  • DOI: 10.1371/journal.pbio.1001540

Reader Comments (1)

Post a new comment on this article

Combination of antibacterials

Posted by pmshah on 26 Apr 2013 at 13:17 GMT

Pena-Miller et al present interesting data. However combination of erythromycin with doxycyclin is, when at all, very rarely prescribed. More interesting would be investigating effects of the most widely used combinations such as amoxicillin + clavulanic acid or piperacillin + tazobactam. Both of these inhibitors are possess not only antibacterial activity but are also potent inducers of beta-lactamases.

The extended spectrum betalactamases producing strains have emerged not only due to extensive use of group three cephalosporins (e.g. cefotaxime, ceftazidime etc.) but also due to uncritical use of beta-lactams in combination with beta-lactamse inhibitors such as clavulanic acid or tazobactam.

To my knowledge there are at least eight combination products (group three cephalosporines + beta-lactamase inhibitors) marketed in the Indian subcontinent. NDM producing strains may have resulted from extensive use of such drug-combinations.

No competing interests declared.